The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Expected Market Size Of The Immunology Biosimilars Market From 2026 To 2030?
The immunology biosimilars market size has experienced rapid expansion recently. It is projected to grow from $8.35 billion in 2025 to $9.45 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 13.2%. The historic period’s growth can be attributed to several factors, including the high cost associated with original biologics, the restricted availability of biosimilar alternatives, the increasing prevalence of autoimmune diseases, the rising adoption of biologics in hospitals and clinical settings, and the rigorous regulatory approval processes for biosimilars.
The immunology biosimilars market size is projected to experience substantial expansion over the coming years. This market is predicted to reach $15.3 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.8%. Factors contributing to this growth during the forecast period include the creation of advanced biosimilar molecules, the broadening of homecare and outpatient treatment alternatives, enhanced regulatory alignment, greater patient understanding and willingness to adopt, and the expansion of online and hospital pharmacy sales routes. Key trends anticipated for the forecast period encompass a growing uptake of monoclonal antibody biosimilars, an increase in the application of fusion protein biosimilars, the wider availability of recombinant protein therapies, an expanding market for interferon-related treatments, and improved access to cost-effective immunology treatments.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25789&type=smp
What Key Drivers Are Influencing The Growth Of The Immunology Biosimilars Market?
The rising occurrence of chronic immunological conditions is anticipated to propel the expansion of the immunology biosimilars market moving forward. These conditions are persistent ailments where the immune system functions improperly, either targeting the body’s own tissues or failing to provide adequate protection. This increase in chronic immunological conditions stems from a growing number of individuals affected by enduring immune system disorders that necessitate continuous care, proactive disease management, and consistent healthcare assistance. Immunology biosimilars assist in managing chronic immunological conditions by offering cost-effective and efficient treatment alternatives, supporting long-term disease control, and enhancing patient accessibility to vital therapies that regulate immune system irregularities. For instance, in November 2023, the Multiple Sclerosis International Federation (MSIF), a UK-based international nonprofit organization dedicated to global MS research and advocacy, reported that an estimated 2.9 million people worldwide were living with multiple sclerosis in 2023. Consequently, the growing frequency of chronic immunological conditions is fueling the development of the immunology biosimilars market.
Which Segments Are Included In The Analysis Of The Immunology Biosimilars Market?
The immunology biosimilars market covered in this report is segmented –
1) By Drug Type: Monoclonal Antibodies, Fusion Proteins, Recombinant Proteins, Interferons, Other Biosimilar Immunomodulators
2) By Disease: Inflammatory Bowel Disease, Arthritis, Other Diseases
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
4) By End User: Hospitals, Clinics, Homecare Settings, Ambulatory Surgical Centers (ASCs)
Subsegments:
1) By Monoclonal Antibodies: Anti-Tumor Necrosis Factor Agents, Anti-Interleukin-6 Agents, Anti-Cluster of Differentiation 20 Agents, Anti-Interleukin-12/23 Agents, Other Monoclonal Antibodies
2) By Fusion Proteins: Etanercept Biosimilars, Other Fusion Protein Biosimilars
3) By Recombinant Proteins: Recombinant Human Insulin, Recombinant Human Growth Hormone, Recombinant Human Erythropoietin, Other Recombinant Protein Biosimilars
4) By Interferons: Interferon Alpha, Interferon Beta, Interferon Gamma
5) By Other Biosimilar Immunomodulators: Interleukin Inhibitors, Janus Kinase Inhibitors, Other Immunomodulatory Biosimilars
Which Trends Are Impacting The Growth Of The Immunology Biosimilars Market?
Leading companies in the immunology biosimilars market are concentrating on developing next-generation biosimilar innovations. These include anticipated interchangeability designation, advanced formulations that enhance stability, and novel delivery systems, all aimed at providing patients with more accessible and effective treatment options. This anticipated interchangeability designation indicates that the biosimilar is expected to meet regulatory standards, enabling its substitution for the reference biologic at the pharmacy level without requiring the prescriber’s intervention. For instance, in February 2025, Sandoz Group AG, a Switzerland-based pharmaceutical company, introduced Pyzchiva (ustekinumab-ttwe), a biosimilar to Stelara, designed for the treatment of chronic autoimmune conditions like plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. This launch, conducted in partnership with Samsung Bioepis Co. Ltd., a South Korea-based biopharmaceutical company, underscores Sandoz’s dedication to increasing access to immunology biosimilars by offering a cost-effective, patient-centric therapy that features multiple dosing options, extended stability, and the unique capability to be re-refrigerated after initial refrigeration.
Which Key Industry Participants Are Active In The Immunology Biosimilars Market?
Major companies operating in the immunology biosimilars market are Pfizer Inc., Novartis AG, Amgen Inc., Sandoz Group AG, Fresenius Kabi AG, Intas Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd., Samsung Bioepis Co. Ltd., Gedeon Richter Plc, Celltrion Inc., Biocon Ltd., Innovent Biologics Inc., Biocad, Mabion S.A.
Read the full immunology biosimilars market report here:
https://www.thebusinessresearchcompany.com/report/immunology-biosimilars-global-market-report
Which Region Is Expected To Register The Fastest Growth In The Immunology Biosimilars Market?
North America was the largest region in the immunology biosimilars market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunology biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Immunology Biosimilars Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=25789&type=smp
Browse Through More Reports Similar to the Global Immunology Biosimilars Market 2026, By The Business Research Company
Biosimilar Market Report 2026
https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report
Biosimilar Market Report 2026
https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report
Bevacizumab Biosimilars Market Report 2026
https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model